Reliv’ International (OTCMKTS:RELV) versus PaxMedica (NASDAQ:PXMD) Critical Survey

Institutional and Insider Ownership

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 7.8% of Reliv’ International shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 30.0% of Reliv’ International shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares PaxMedica and Reliv’ International”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29 million	($6.09)	0.00
Reliv’ International	$35.06 million	0.11	-$440,000.00	($0.09)	-25.00

Reliv’ International has higher revenue and earnings than PaxMedica. Reliv’ International is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PaxMedica and Reliv’ International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Reliv’ International	-0.61%	-1.89%	-1.31%

Risk & Volatility

PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the S&P 500. Comparatively, Reliv’ International has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500.

Summary

Reliv’ International beats PaxMedica on 8 of the 10 factors compared between the two stocks.

About PaxMedica

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

About Reliv’ International

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.